EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Anti-CD45 PBD-based antibody-drug conjugates are effective targeted conditioning agents for gene therapy and stem cell transplant

Jenny Yeung, Aiyin Liao, Matthew Shaw, Soraia Silva, Winston Vetharoy, Diego Leon Rico, Ian Kirby, Francesca Zammarchi, Karin Havenith, Lolke de Haan, Patrick H van Berkel, Neil Sebire und 6 weitere

Molecular Therapy · 2024-06 · 32 (6) · 1672-1686

DOI: 10.1016/j.ymthe.2024.03.032 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Molecular Therapy, 2024-06. Verfasst von Jenny Yeung und 17 weiteren Autor:innen. Beteiligte Einrichtung: UCL Great Ormond Street Institute of Child Health, Zayed Centre of Research, 20 Guilford Street, London WC1N 1DZ, UK; UCL Cancer Institute, 72 Huntle…. Hauptthemen laut MEDLINE: Immunoconjugates, Leukocyte Common Antigens, Genetic Therapy, Hematopoietic Stem Cell Transplantation. Die Arbeit wurde bisher 25-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Wellcome Trust, University College London, Children with Cancer UK.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Stem cell gene therapy and hematopoietic stem cell transplantation (SCT) require conditioning to ablate the recipient's hematopoietic stem cells (HSCs) and create a niche for gene-corrected/donor HSCs. Conventional conditioning agents are non-specific, leading to off-target toxicities and resulting in significant morbidity and mortality. We developed tissue-specific anti-human CD45 antibody-drug conjugates (ADCs), using rat IgG2b anti-human CD45 antibody clones YTH24.5 and YTH54.12, conjugated to cytotoxic pyrrolobenzodiazepine (PBD) dimer payloads with cleavable (SG3249) or non-cleavable (SG3376) linkers. In vitro, these ADCs internalized to lysosomes for drug release, resulting in potent and specific killing of human CD45+ cells. In humanized NSG mice, the ADCs completely ablated human HSCs without toxicity to non-hematopoietic tissues, enabling successful engraftment of gene-modified autologous and allogeneic human HSCs. The ADCs also delayed leukemia onset and improved survival in CD45+ tumor models. These data provide proof of concept that conditioning with anti-human CD45-PBD ADCs allows engraftment of donor/gene-corrected HSCs with minimal toxicity to non-hematopoietic tissues. Our anti-CD45-PBDs or similar agents could potentially shift the paradigm in transplantation medicine that intensive chemo/radiotherapy is required for HSC engraftment after gene therapy and allogeneic SCT. Targeted conditioning both improve the safety and minimize late effects of these procedures, which would greatly increase their applicability.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ImmunoconjugatesLeukocyte Common AntigensGenetic TherapyHematopoietic Stem Cell TransplantationBenzodiazepinesAnimalsHumansMiceHematopoietic Stem CellsRatsTransplantation ConditioningDisease Models, AnimalAntibodies, MonoclonalPyrroles

Stichwörter der Autor:innen

ADCCD45SCTantibody-drug conjugateconditioninggene therapyleukemia

Substanzen

ImmunoconjugatesLeukocyte Common AntigensBenzodiazepinespyrrolo(2,1-c)(1,4)benzodiazepineAntibodies, MonoclonalPyrroles

Autor:innen und Institutionen

  • UCL Great Ormond Street Institute of Child Health, Zayed Centre of Research, 20 Guilford Street, London WC1N 1DZ, UK; UCL Cancer Institute, 72 Huntley Street, London, UK.
  • UCL Great Ormond Street Institute of Child Health, Zayed Centre of Research, 20 Guilford Street, London WC1N 1DZ, UK.
  • ADC Therapeutics UK (Ltd), Imperial College White City Campus, 84 Wood Lane, London W12 0BZ, UK.
  • Great Ormond Street Hospital for Children NHS Foundation Trust, Great Ormond Street, London WC1N 1JH, UK.
  • UCL Great Ormond Street Institute of Child Health, Zayed Centre of Research, 20 Guilford Street, London WC1N 1DZ, UK; Great Ormond Street Hospital for Children NHS Foundation Trust, Great Ormond Street, London WC1N 1JH,…
  • UCL Cancer Institute, 72 Huntley Street, London, UK.

Förderung

  • Wellcome Trust
  • University College London
  • Children with Cancer UK
  • Horizon 2020
  • National Institute for Health and Care Research
  • UCL Cancer Institute
  • Centro de Investigaciones en Optica

Zitieren

APA

Yeung, J., Liao, A., Shaw, M., Silva, S., Vetharoy, W., Rico, D. L., Kirby, I., Zammarchi, F., Havenith, K., de Haan, L., van Berkel, P. H., Sebire, N., Ogunbiyi, O. K., Booth, C., Gaspar, H. B., Thrasher, A. J., Chester, K. A., & Amrolia, P. J. (2024). Anti-CD45 PBD-based antibody-drug conjugates are effective targeted conditioning agents for gene therapy and stem cell transplant. Molecular Therapy, 32(6), 1672-1686. https://doi.org/10.1016/j.ymthe.2024.03.032

Vancouver

Yeung J, Liao A, Shaw M, Silva S, Vetharoy W, Rico DL, et al. Anti-CD45 PBD-based antibody-drug conjugates are effective targeted conditioning agents for gene therapy and stem cell transplant. Molecular Therapy. 2024;32(6):1672-1686. doi:10.1016/j.ymthe.2024.03.032

BibTeX
@article{Yeung2024,
  author = {Yeung, Jenny and Liao, Aiyin and Shaw, Matthew and Silva, Soraia and Vetharoy, Winston and Rico, Diego Leon and Kirby, Ian and Zammarchi, Francesca and Havenith, Karin and de Haan, Lolke and van Berkel, Patrick H and Sebire, Neil and Ogunbiyi, Olumide K and Booth, Claire and Gaspar, H Bobby and Thrasher, Adrian J and Chester, Kerry A and Amrolia, Persis J},
  title = {Anti-CD45 PBD-based antibody-drug conjugates are effective targeted conditioning agents for gene therapy and stem cell transplant},
  journal = {Molecular Therapy},
  year = {2024},
  volume = {32},
  number = {6},
  pages = {1672--1686},
  doi = {10.1016/j.ymthe.2024.03.032}
}
Kostenlos starten →